FDA OKs Ninth Humira Biosimilar, With Interchangeability FDA OKs Ninth Humira Biosimilar, With Interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news
FDA Grants Interchangeable Designation to Pfizer ’s Biosimilar Abrilada
NEW YORK, October 5, 2023– Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). The... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 5, 2023 Category: Drugs & Pharmacology Source Type: news
CVS Joins Race to Sell Cheaper,'Biosimilar' Drugs
CVS will start selling less expensive, "biosimilar" versions of certain prescription medications, starting with its own version of Humira early next year, the drugstore chain said this week. The company is focusing on cheaper versions of biologic medications, a type of drug that's made from living…#cvs #humira #botox #sandoz #ameetsarpatwari #harvardmedicalschool #markcuban #premshah #biosimilar #fda (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2023 Category: Consumer Health News Source Type: news
CVS Health Launches Company To Produce Cheaper ‘Biosimilar’ Versions Of Expensive Biotech Drugs
CVS Health is launching a new company that will work directly with drug makers to produce and commercialize “biosimilar” drugs, the less expensive versions of expensive brand prescriptions derived from biotechnology. The new of the new company, Cordavis, will operate as “a wholly owned subsidiary…#cvshealth #cordavis #cvs #fda #humira (Source: Reuters: Health)
Source: Reuters: Health - August 23, 2023 Category: Consumer Health News Source Type: news
CVS pushes into making cheaper versions of complex drugs with new discount Humira
CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira that will sell for 80% below the price of the brand-named drug. The move is part of the company's new venture focused on securing, and in some cases co-producing,…#cvshealth #sandoz #humira #premshah #cvshealthevp #cvs #redoak #cardinalhealth #cordavis #novartis (Source: Reuters: Health)
Source: Reuters: Health - August 23, 2023 Category: Consumer Health News Source Type: news
Is Growth Priced into Amgen Stock after Earnings Beat?
Amgen Inc. NASDAQ: AMGN delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023. But heading into earnings, analyst sentiment suggests that all the growth may already be priced into…#amgeninc #amgn #amgen #abbvieinc #abbv #humira #amjevita #fda #evenity #repatha (Source: Reuters: Health)
Source: Reuters: Health - August 7, 2023 Category: Consumer Health News Source Type: news
The Patent Cliff Is Why AbbVie Is Moving Higher
AbbVie NYSE: ABBV shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. The fear of rapidly declining Humira sales was not offset by hope driven by new products such as Skyrizi and Rinvoq. The takeaway for today is that Humira sales may already be…#humira #rinvoq #skrizi #abbvie #yoy #skyriziandrinvoq #hematologyoncology #botox #eps #marketbeatcom (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
AbbVie may see less pain from Humira sales decline as rival lags
is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction. Humira sales are likely to decline when the company reports on Thursday but that would mostly be due to the discounts…#abbvieinc #humira #abbvie #amgeninc #paribas #navannty #cvscaremark #cigna #amgen #rinvoq (Source: Reuters: Health)
Source: Reuters: Health - July 26, 2023 Category: Consumer Health News Source Type: news
Humira Biosimilars: Five Things to Know Humira Biosimilars: Five Things to Know
The launch of eight adalimumab biosimilars so far this year ended Humira ' s 20-year monopoly, but it ' s not clear yet if these discounted drugs will save patients money.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 18, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Treatment Effect of Tofacitinib, Adalimumab Compared in RA
WEDNESDAY, July 12, 2023 -- For adults with rheumatoid arthritis (RA), there is a modest reduction in the mean Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) at three months for patients receiving tofacitinib (TOF) versus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2023 Category: Pharmaceuticals Source Type: news
Cigna to Add 3 Humira Biosimilars to Drug Reimbursement List Cigna to Add 3 Humira Biosimilars to Drug Reimbursement List
Cigna Group ' s Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie ' s blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2023 Category: Consumer Health News Tags: Dermatology News Source Type: news
Mark Cuban's Online Pharmacy Set to Launch Humira Biosimilar Mark Cuban's Online Pharmacy Set to Launch Humira Biosimilar
Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences ' s biosimilar version of Humira.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2023 Category: Consumer Health News Tags: Rheumatology News Source Type: news
India's Biocon Biologics Launches Biosimilar for Humira in US India's Biocon Biologics Launches Biosimilar for Humira in US
India ' s Biocon Biologics said on Monday it has launched a biosimilar version of AbbVie ' s blockbuster rheumatoid arthritis drug Humira in the United States.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2023 Category: Consumer Health News Tags: Dermatology News Source Type: news
Humira, the world ’s No. 1 drug, finally faces low-cost competitors
If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.#humira (Source: Reuters: Health)
Source: Reuters: Health - July 5, 2023 Category: Consumer Health News Source Type: news
Biocon Biologics launches biosimilar adalimumab in US
Adalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie for 2022, making it the world ’s top-selling non-COVID prescription drug until recently. HULIO is available at a list price (Wholesale Acquisition Cost) of 5% below the current Humira list price. Adalimumab-fkjp is also available at a list price of approximately 85% below the current Humira list price. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 4, 2023 Category: Pharmaceuticals Source Type: news
